Last updated: September 9, 2026
Answer a few questions to find platinum-resistant ovarian cancer trials matched to your FRα, Cyclin E1, and treatment history.
A thorough search takes ~15 minutes — we'll email your results. No sign-up.
Find matching trials →Ovarian cancer is called platinum-resistant when it recurs or progresses within 6 months of finishing platinum-based chemotherapy (carboplatin or cisplatin). If it comes back more than 6 months later, it is platinum-sensitive and platinum can usually be re-used; if it grows during platinum treatment, it is platinum-refractory. This 6-month "platinum-free interval" is the single most important number for choosing your next treatment and for deciding which trials you qualify for.
Platinum-resistant ovarian cancer (PROC) is the setting where standard chemotherapy works least well — historically single-agent chemo produces responses in roughly 1 in 10 patients — which is exactly why it is one of the most active clinical-trial areas in oncology. This page focuses only on the platinum-resistant/refractory setting. For the full disease picture across all settings, see the main ovarian cancer trials page.
Knowing the current standard of care helps you weigh a trial against it. In platinum-resistant disease the goals are usually tumor control, symptom relief, and quality of life rather than cure.
Two trials established Elahere as the first ADC approved for ovarian cancer, both in FRα-high platinum-resistant disease:
MIRASOL (Phase 3, confirmatory) — mirvetuximab vs. investigator's-choice chemotherapy in FRα-high, platinum-resistant, high-grade serous ovarian cancer:
SORAYA (Phase 2, accelerated-approval basis) — single-arm, FRα-high platinum-resistant disease after 1–3 prior therapies: objective response rate 32.4%, median duration of response 6.9 months.
Sources: MIRASOL (Moore et al., N Engl J Med 2023); SORAYA (Matulonis et al., J Clin Oncol 2023). Elahere is FDA-approved for FRα-positive, platinum-resistant ovarian cancer; eligibility depends on an FRα companion-diagnostic test. Trial results describe FRα-high populations and may not apply to FRα-low disease.
Many of the most promising platinum-resistant trials only enroll patients with a specific biomarker. Ask your oncologist which of these you have been tested for — they determine which trials below you can join.
The platinum-resistant landscape in 2026 is dominated by antibody-drug conjugates (ADCs) and biomarker-selected targeted agents. Trials below are recruiting; phase is noted for each. Confirm current status and eligibility with the study team — a trial's status and locations can change.
ADCs deliver chemotherapy directly to tumor cells via a targeting antibody — the approach that produced Elahere. Each of these targets a different antigen (FRα, CDH6, TROP2, HER2, EGFR/HER3), so which one fits depends on what your tumor expresses.
These require Cyclin E1 overexpression or CCNE1 amplification — ask whether your tumor has been tested.
This is a curated snapshot, not the full list. There are 90+ platinum-resistant ovarian cancer trials recruiting, and which ones fit depends on your FRα and Cyclin E1 status, prior lines of therapy, histology, and country. Run a personalized match to see the trials you actually qualify for.
What does platinum-resistant ovarian cancer mean?
Ovarian cancer is platinum-resistant when it recurs or progresses within 6 months of completing platinum-based chemotherapy (carboplatin or cisplatin). Recurrence more than 6 months later is called platinum-sensitive; growth during platinum treatment is called platinum-refractory. The length of this "platinum-free interval" drives both your treatment choices and your trial eligibility.
What trials are open for platinum-resistant ovarian cancer?
The platinum-resistant setting is one of the most active research areas in oncology, led by antibody-drug conjugates and biomarker-selected agents. Recruiting Phase 3 examples include FRα-targeted ADCs (AZD5335 vs mirvetuximab, NCT07218809), raludotatug deruxtecan (NCT06161025), TROP2 ADC SHR-A1921 (NCT06394492), the EGFR×HER3 bispecific ADC BL-B01D1 (NCT06994195), Cyclin E1-selected agents INCB123667 (NCT07214779) and azenosertib (NCT07546500), and oncolytic-virus combinations (Olvi-Vec, NCT05281471). Which ones fit you depends on your biomarkers and prior treatment — paste your summary into ClinTrialFinder for a personalized match.
What is the standard treatment for platinum-resistant ovarian cancer?
For FRα-positive tumors, Elahere (mirvetuximab soravtansine) — the first FDA-approved ADC for ovarian cancer — is a standard option and improved survival versus chemotherapy in the confirmatory trial. Otherwise, single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin, topotecan, or gemcitabine), often combined with bevacizumab (the AURELIA regimen), is standard. Treatment goals are usually tumor control, symptom relief, and quality of life. A clinical trial is a reasonable option to consider at any point in this setting.
Why does folate receptor alpha (FRα) testing matter?
FRα expression, measured by IHC on your tumor, determines whether Elahere and several next-generation FRα-targeted ADC trials (such as AZD5335) are options for you. Trials frequently enroll by FRα-high versus FRα-low status, making it the most important single biomarker test in platinum-resistant ovarian cancer. If you don't know your FRα status, ask your oncologist whether it can be tested.
Do PARP inhibitors still work once my cancer is platinum-resistant?
PARP inhibitors (olaparib, niraparib, rucaparib) are mainly used as maintenance in platinum-sensitive disease and are less effective once cancer becomes platinum-resistant, especially after prior PARP exposure. Your BRCA1/2 and HRD status still matter for trial stratification and for understanding your options, but in the resistant setting the most active trials are ADCs and biomarker-selected targeted agents rather than PARP inhibitors.
Find Platinum-Resistant Ovarian Cancer Trials Matched to Your Situation
Use ClinTrialFinder's AI-powered matching to find trials based on your FRα and Cyclin E1 status, histology, prior lines of therapy, and country.
Find Matching Trials